Aripiprazole regulatory update

FDA issued a complete response letter for an NDA from Otsuka for the pharma’s antipsychotic Abilify aripiprazole with an ingestible sensor from Proteus in a single tablet. The companies said the letter requested additional human factors investigations and performance data under the conditions in which the digital medicine is likely to be used. ...